Jacobson Pharma Dividends and Buybacks
Dividend criteria checks 4/6
Jacobson Pharma is a dividend paying company with a current yield of 7.59% that is well covered by earnings.
Key information
7.6%
Dividend yield
0.2%
Buyback Yield
| Total Shareholder Yield | 7.8% |
| Future Dividend Yield | 9.1% |
| Dividend Growth | 13.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 59% |
Recent dividend and buyback updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Jacobson Pharma Corporation Limited's (HKG:2633) CEO For Now
Jul 21
Jacobson Pharma Corporation Limited (HKG:2633) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
Jul 02Here's Why We Think Jacobson Pharma (HKG:2633) Might Deserve Your Attention Today
Jun 13Jacobson Pharma Corporation Limited's (HKG:2633) 28% Price Boost Is Out Of Tune With Earnings
Jan 06There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 2633 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 2633's dividend payments have increased, but the company has only paid a dividend for 9 years.
Dividend Yield vs Market
| Jacobson Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (2633) | 7.6% |
| Market Bottom 25% (HK) | 2.3% |
| Market Top 25% (HK) | 6.7% |
| Industry Average (Pharmaceuticals) | 1.9% |
| Analyst forecast (2633) (up to 3 years) | 9.1% |
Notable Dividend: 2633's dividend (7.59%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.34%).
High Dividend: 2633's dividend (7.59%) is in the top 25% of dividend payers in the Hong Kong market (6.7%)
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (59.4%), 2633's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: At its current cash payout ratio (78.8%), 2633's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 20:19 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jacobson Pharma Corporation Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cho Ming Lau | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Fangfang Li | Cinda International Research Limited |